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PERSPECTIVE
Understanding metabolic lexibility: a 
potential key to unlocking metabolic 
therapies in amyotrophic lateral 
sclerosis? 
he role of metabolism in amyotrophic lateral sclerosis (ALS): ALS, is a 
predominantly sporadic, neurological disorder resulting in degeneration of 
both upper and lower motor neurons, resulting in the progressive failure 
of the neuromuscular system. he lifetime risk factor for developing ALS 
sits between 1 in 300 and 1 in 400. However, due to the speed of the disease 
course (2–3 years post-diagnosis) and the lack of efective therapies, ALS is 
still classiied as a rare disease. It is well established that ALS afects energy 
generation not only in the central nervous system (CNS) but in the periph-
ery (Vandoorne et al., 2018). However, the question of whether metabolic 
dysfunction is the primary cause of ALS or a secondary effect has been 
the topic of discussion in the ield for many years. Metabolic dysfunction 
is observed in cellular models of the disease, early in the disease course in 
animal models and in both patient post-mortem tissues and bioluids. How-
ever, over the last 10–15 years, many of the ALS genes identiied have been 
linked to RNA processing or function. hese include TDP43 (TARDBP or 
TAR DNA binding protein 43 a key pathological marker of ALS), fused in 
sarcoma (FUS) and an intronic expansion in C9orf72 which accounts for 
approximately 10% of all ALS and frontotemporal dementia cases, including 
a signiicant proportion of both familial and apparently sporadic cases. his 
leads to the question of whether RNA processing defects are the key patho-
genic event in sporadic ALS and how this relates, if at all, to energy metab-
olism defects? Indeed, a recent publication from Vandoorne et al. (2019) 
indicated that induced pluripotent stem cell derived motor neurons with an 
ALS causing FUS mutation did not show metabolic dysfunction in spite of 
recapitulating other aspects of the disease (Guo et al., 2017). However, and 
as stated by the authors, their results do not discount the role of metabolic 
dysfunction in motor neuron dysfunction. Intriguing, the lack of metabolic 
dysfunction in these motor neurons potentially points to non-neuronal cells 
such as astrocytes, or muscle as the source of metabolic dysfunction in ALS 
(Dupuis et al., 2009; Allen et al., 2019a). A classical metabolomic approach 
has been taken by many researchers to try and uncover the role of energy 
dysfunction in ALS. Although it is clear our neuronal and non-neuronal 
models of ALS have a distinct metabolic profile compared to controls, a 
lack of consistency between studies have hampered the field in terms of 
metabolic biomarker identiication. 15 years on from the irst metabolomic 
study in ALS (Rozen et al., 2005) the ield is still unclear regarding how the 
disease afects the many catabolic pathways that feed into the major energy 
generating systems in the cell. If we regard ALS as primarily a RNA pro-
cessing/export disease for example, this could either directly or indirectly, 
affect the transcript levels or the splicing of multiple components within 
these catabolic pathways. Understanding how ALS afects global cellular ca-
tabolism would allow researchers to manipulate catabolism therapeutically 
or nutritionally to increase carbon low into the glycolytic or mitochondrial 
energy generating pathways. If metabolic dysfunction is not the cause of 
ALS then it certainly is an early, important cause of the disease because it 
can afect disease progression rates (Steyn et al., 2018). herefore, in depth 
understanding of the metabolic pathways and how they are afected in ALS 
could lead to therapies that slow down the disease progression and increase 
the quality of life of people with the disease.
Metabolic lexibility: In our laboratory we have used ibroblasts as an initial 
human derived model of ALS. he major criticism of this model is that it is 
not a CNS cell and that ibroblast toxicity is not observed in ALS. However, 
we and others have found that metabolically, ibroblasts recapitulate some 
of the pathogenic dysfunction observed in the CNS including metabolic 
dysfunction (Allen et al., 2019a). In our laboratory this led to the question, 
what can a ibroblast do metabolically that an astrocyte for example cannot? 
We found that fibroblasts isolated from superoxide dismutase-1 (SOD1) 
ALS patients had reduced mitochondrial capacity (Allen et al., 2014). How-
ever, unlike astrocytes and motor neurons (Figure 1), ibroblasts were able 
to upregulate glycolytic flux to maintain energy production. This raised 
the possibility that inherent metabolic lexibility may play a protective role 
against ALS and may be linked to polygenicity and/or CNS speciic disease 
modifying factors. Rather than ALS being solely monogenic in nature, the 
disease itself, what age it manifests and the speed of progression may be 
linked to a number of interacting rare variants, which in combination with 
environmental factors may act as CNS disease modifiers which influence 
disease onset and progression (Al-Chalabi et al., 2014). he result of these 
interactions may be patient group or even patient to patient specific and 
may influence how patients respond to for example, dysfunction in RNA 
processing, drugs or nutritional intervention (Allen et al., 2019a), which 
could impact on the overall effectiveness of dietary or therapeutic inter-
ventions. hese potential disease modifying interactions could be respon-
sible for the disease heterogeneity observed in ALS patients. It is clear that 
different genetic backgrounds or levels of gene overexpression can affect 
factors such as disease onset or survival in animal models of ALS. However, 
it could be argued that patient heterogeneity is not recapitulated to the same 
extent, which contributes to the lack of therapeutic translation observed 
in the ALS ield between animal models and patients. herefore, a lack of 
a successful translatable animal model makes the use of human models of 
disease such as ibroblasts all the more relevant, especially as they can be 
readily reprogrammed into inducible neuronal progenitor cells (Meyer et 
al., 2014). Induced neuronal progenitor cell reprogramming overcomes the 
challenging phenotypic inconsistency of clonal variation oten observed in 
induced pluripotent stem cells. Furthermore, the reprogramming does not 
reset the epigenetic state of the ibroblasts so inherent aging phenotypes are 
retained which reduces the reliance on post-mortem tissue (Mertens et al., 
2015).
Phenotypic metabolic screening: The idea of investigating flexibility in 
ALS originated from our early laboratory work in ibroblasts in 2014 and 
came to fruition in two papers in 2019 (Allen et al., 2019a, b). In these 
studies we utilized phenotypic metabolic screening technology developed 
by Biolog Inc. (Hayward CA. USA), which is an alternative to the classic 
metabolomic approach and had not been previously used in the ALS ield. 
he technology generates a kinetic metabolic proile of the cell by removing 
glucose and supplementing in the case of their PM-M1 carbohydrate plate, 
with energy substrates from 91 diferent points in the catabolic pathways 
simultaneously. This global profiling approach where cells are starved of 
glucose and fed individual metabolic substrates allowed us to, for the irst 
time in the ALS field, directly measure metabolic flexibility in human 
models of C9orf72 and sporadic ALS. Moreover, using fibroblast-derived 
induced neuronal progenitor cells diferentiated into iAstrocytes we were 
able to assess how the metabolic proile and metabolic lexibility was altered 
by the reprogramming process. We showed distinct metabolic proiles be-
tween fibroblasts and iAstrocytes and that patient fibroblasts maintained 
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Figure 1 Cortical astrocytes at p1 and cortical 
neurons at E15 were isolated from C75/BL-6 G93A 
SOD1 mice and cultured. 
15,000 astrocytes or 75,000 neurons per well were 
analyzed for their mitochondrial respiration (A) and 
glycolytic lux (B) using an XF24 bioanalyser as pre-
viously described (Allen et al., 2019a). Data presented 
as one data point per independent biological replicate 
(each data point being an average of 3–4 wells of a 
24-well plate), data presented with mean and stan-
dard deviation. *P ≤ 0.05, using parametric t-test 
analysis. ECAR: Extracellular acidiication rate; NTG: 
non-transgenic; OCR: oxygen consumption rate; 
SOD1: superoxide-dismutase-1; TG: transgenic. 
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their metabolic lexibility compared to controls whilst metabolic lexibility 
was reduced in C9orf72 and sporadic ALS iAstrocytes which contributed 
to starvation induced toxicity. Using this global profiling approach com-
bined with principal component analysis and heat mapping, we were able 
to identify the catabolic pathways that were altered between controls and 
ALS cases in iAstrocytes. We found dysfunction in catabolic pathways that 
had not been implicated in ALS before including nucleoside, glycogen and 
fructose catabolism. Probing of the enzymes/proteins in these pathways elu-
cidated new targets for both C9orf72 and sporadic ALS including adenosine 
deaminase, glycogen phosphorylase, phosphoglucomutase and glyoxalase-1 
(Allen et al., 2019a, b). All of these pathways contributed to a loss of met-
abolic flexibility in the ALS iAstrocytes. However, a number of primarily 
mitochondrial energy substrates that were reduced in the ALS iAstrocytes 
showed control level of enzymes involved in their catabolism. So we asked 
the question, does membrane transport of energy substrates contribute to 
metabolic lexibility? We therefore utilized a newly established technologi-
cal advancement from Biolog Inc. which probes for mitochondrial function 
by saponin treating cells and feeding the cells a variety of cytosolic and 
mitochondrial substrates. We found that those mitochondrial energy sub-
strates that were afected in the whole cell screen were unafected in saponin 
treated cells and that C9orf72 iAstrocytes had alerted saponin sensitivity. As 
saponin functions by binding cholesterol, our results suggested that choles-
terol levels may be altered in C9orf72 ALS which would afect membrane 
lipid structures, membrane transport levels and therefore, energy substrate 
membrane transport. These results showed that both efficient catabolism 
and membrane transport of energy substrates are crucial for efective met-
abolic lexibility in the CNS. Moreover, disruption to these processes leads 
to toxicity in the event of disrupted metabolic fuel supplies to the glycolytic 
and mitochondrial energy generation pathways. 
Nutritional supplementation in ALS: Nutritional supplementation based 
on a sound understanding of how ALS afects the catabolic pathways has the 
potential to, if not cure the disease, have a signiicant impact on disease pro-
gression and quality of life. A number of trials are in progress including the 
HighCALS trial (RP-PG-1016-20006), which seeks to increase calorie intake 
in ALS patients and a high fat supplement trial in Europe (NCT02306590). 
This aims to give ALS patients a high fat diet which has been shown to 
be beneicial in the SOD1 mouse model of the disease. Only time will tell 
whether they are efective and in what subset of patients. Recently, inosine 
has emerged as a potential nutritional supplement in the ALS ield, based 
on previously encouraging studies of inosine as a potential source or the 
antioxidant urate/uric acid in Parkinson’s disease. However, a recent SURE-
PD3, Phase III clinical trial in Parkinson’s disease was halted due to a lack of 
eicacy and it remains to be seen how an inosine safety study in the United 
States (SURE-ALS2) will pan out. In our in vitro study (Allen et al., 2019a) 
we found that inosine supplementation in ALS iAstrocytes led to an increase 
in uric acid levels in all cases. However, inosine supplementation was not 
bioenergetically beneicial in all ALS case derived iAstrocytes. Intriguing, 
only those ALS iAstrocytes which responded bioenergetically to inosine be-
came less toxic towards motor neurons in co-culture compared to those that 
did not respond bioenergetically. herefore, elucidating the correct mech-
anism of action of any nutritional intervention is key before embarking on 
clinical trials. As is the ability to sub-classify patients, not based on ALS as 
a monogenic disease but based on ALS as a polygenic, multivariate disease 
with modifying factors that inluence metabolic lexibility and the response 
to nutritional intervention or therapeutic intervention. his is a real beneit 
of our induced neuronal progenitor cell model of ALS, not only do they 
retain their aging phenotype, they are genetically distinct and unlike the 
homogenous animal models, recapitulate the ALS case to case heterogeneity 
observed in clinical trials, which negatively afect statistically positive sur-
vival outcomes.
In short, sub-classifying ALS patients based on their genetically influ-
enced cellular response to the disease (which ties in with metabolic flex-
ibility) or their response to therapeutic intervention, has the potential to 
open the possibility of designing patient specific therapeutic approaches 
to improve prognosis for people with ALS. Taking a phenotypic metabolic 
functional approach in patient-derived cells enables researchers to function-
ally metabolically ingerprint complex sporadic diseases such as ALS. his 
“metabotyping” bridges the gap between environmental inluences on the 
genome and the heterogenic functional outcomes which has so far reduced 
our translational eicacy in this devastating neurological disease.  
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